Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mobiles apps

- PMLiVE

Novo bolstered by new diabetes, obesity products

Danish drug-maker has now raised its full-year sales forecast

- PMLiVE

Novo Nordisk taps Noom for digital help with its push into obesity

Could help to strengthen Saxenda franchise in treatment of obesity

- PMLiVE

Novo Nordisk gets FDA okay for new diabetes hope

Potential to combat increasing competition and pricing pressures

- PMLiVE

Novo follows Sanofi, Lilly with insulin price cut in US

Price cut will be effective from January 2020

- PMLiVE

Novo Nordisk shareholder revolt reaches Europe

Accused of lacking transparency over pricing pressures

- PMLiVE

Novo Nordisk boosted by new type 2 diabetes launches

Rapid uptake of newcomer Ozempic aids growth

- PMLiVE

The fight for affordable insulin

Activists are organised, and demanding action on US insulin prices - and pointing the finger at pharma

- PMLiVE

EMA clears Novo Nordisk’s long-acting haemophilia A drug

Entering newly competitive market

- PMLiVE

Novo Nordisk targets renewable energy switch by 2030

Huge solar panel array helps transition

- PMLiVE

Q&A: Niels Lund

PME interviews Novo Nordisk's Vice President, Health Advocacy

- PMLiVE

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin price nearly tripled between 2002 and 2013

- PMLiVE

Novo uses voucher for speedy answer on oral semaglutide

Oral version of Ozempic could be diabetes market leader

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links